Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Genetic Discrimination Between LADA and Childhood-Onset Type 1 Diabetes Within the MHC.

Mishra R, Åkerlund M, Cousminer DL, Ahlqvist E, Bradfield JP, Chesi A, Hodge KM, Guy VC, Brillon DJ, Pratley RE, Rickels MR, Vella A, Ovalle F, Harris RI, Melander O, Varvel S, Hakonarson H, Froguel P, Lonsdale JT, Mauricio D, Schloot NC, Khunti K, Greenbaum CJ, Yderstræde KB, Tuomi T, Voight BF, Schwartz S, Boehm BO, Groop L, Leslie RD, Grant SFA.

Diabetes Care. 2020 Feb;43(2):418-425. doi: 10.2337/dc19-0986. Epub 2019 Dec 16.

PMID:
31843946
2.

Concentrated insulins in current clinical practice.

Schloot NC, Hood RC, Corrigan SM, Panek RL, Heise T.

Diabetes Res Clin Pract. 2019 Feb;148:93-101. doi: 10.1016/j.diabres.2018.12.007. Epub 2018 Dec 21. Review.

3.

First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes.

Cousminer DL, Ahlqvist E, Mishra R, Andersen MK, Chesi A, Hawa MI, Davis A, Hodge KM, Bradfield JP, Zhou K, Guy VC, Åkerlund M, Wod M, Fritsche LG, Vestergaard H, Snyder J, Højlund K, Linneberg A, Käräjämäki A, Brandslund I, Kim CE, Witte D, Sørgjerd EP, Brillon DJ, Pedersen O, Beck-Nielsen H, Grarup N, Pratley RE, Rickels MR, Vella A, Ovalle F, Melander O, Harris RI, Varvel S, Grill VER; Bone Mineral Density in Childhood Study, Hakonarson H, Froguel P, Lonsdale JT, Mauricio D, Schloot NC, Khunti K, Greenbaum CJ, Åsvold BO, Yderstræde KB, Pearson ER, Schwartz S, Voight BF, Hansen T, Tuomi T, Boehm BO, Groop L, Leslie RD, Grant SFA.

Diabetes Care. 2018 Nov;41(11):2396-2403. doi: 10.2337/dc18-1032. Epub 2018 Sep 25.

4.

Response to the comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 trials".

Leslie RD, Pozzilli P, Peters AL, Buzzetti R, Shankar SS, Milicevic Z, Pavo I, Lebrec J, Martin S, Schloot NC.

Diabetes Obes Metab. 2018 Sep;20(9):2319-2320. doi: 10.1111/dom.13366. Epub 2018 Jun 10. No abstract available.

PMID:
29781106
5.

Characterization of circulating leukocytes and correlation of leukocyte subsets with metabolic parameters 1 and 5 years after diabetes diagnosis.

Apostolopoulou M, Menart-Houtermans B, Ruetter R, Nowotny B, Gehrmann U, Markgraf D, Szendroedi J, Schloot NC, Roden M.

Acta Diabetol. 2018 Jul;55(7):723-731. doi: 10.1007/s00592-018-1143-x. Epub 2018 Apr 16.

PMID:
29663084
6.

Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.

Pozzilli P, Leslie RD, Peters AL, Buzzetti R, Shankar SS, Milicevic Z, Pavo I, Lebrec J, Martin S, Schloot NC.

Diabetes Obes Metab. 2018 Jun;20(6):1490-1498. doi: 10.1111/dom.13237. Epub 2018 Feb 21.

PMID:
29377522
7.

Metabolic Characteristics of Recently Diagnosed Adult-Onset Autoimmune Diabetes Mellitus.

Zaharia OP, Bobrov P, Strassburger K, Bódis K, Karusheva Y, Scholz M, Markgraf DF, Burkart V, Schloot NC, Müssig K, Szendroedi J, Roden M; GDS Group.

J Clin Endocrinol Metab. 2018 Feb 1;103(2):429-437. doi: 10.1210/jc.2017-01706.

PMID:
29220505
8.

Relative contribution of type 1 and type 2 diabetes loci to the genetic etiology of adult-onset, non-insulin-requiring autoimmune diabetes.

Mishra R, Chesi A, Cousminer DL, Hawa MI, Bradfield JP, Hodge KM, Guy VC, Hakonarson H; Bone Mineral Density in Childhood Study, Mauricio D, Schloot NC, Yderstræde KB, Voight BF, Schwartz S, Boehm BO, Leslie RD, Grant SFA.

BMC Med. 2017 Apr 25;15(1):88. doi: 10.1186/s12916-017-0846-0.

9.

Inverse Relationship Between Organ-Specific Autoantibodies and Systemic Immune Mediators in Type 1 Diabetes and Type 2 Diabetes: Action LADA 11.

Schloot NC, Pham MN, Hawa MI, Pozzilli P, Scherbaum WA, Schott M, Kolb H, Hunter S, Schernthaner G, Thivolet C, Seissler J, Leslie RD; Action LADA Group.

Diabetes Care. 2016 Nov;39(11):1932-1939. Epub 2016 Aug 29.

PMID:
27573939
10.

Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment.

Leslie RD, Palmer J, Schloot NC, Lernmark A.

Diabetologia. 2016 Jan;59(1):13-20. doi: 10.1007/s00125-015-3789-z. Review.

PMID:
26498592
11.

Risk of severe hypoglycemia in sulfonylurea-treated patients from diabetes centers in Germany/Austria: How big is the problem? Which patients are at risk?

Schloot NC, Haupt A, Schütt M, Badenhoop K, Laimer M, Nicolay C, Reaney M, Fink K, Holl RW.

Diabetes Metab Res Rev. 2016 Mar;32(3):316-24. doi: 10.1002/dmrr.2722. Epub 2015 Nov 20.

PMID:
26409039
12.

[Reducing blood glucose values saves diabetic patients' eyes].

Schloot NC.

MMW Fortschr Med. 2015 Jul 23;157(13):40. doi: 10.1007/s15006-015-3348-z. German. No abstract available.

PMID:
26206032
13.

Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept.

Simon MC, Strassburger K, Nowotny B, Kolb H, Nowotny P, Burkart V, Zivehe F, Hwang JH, Stehle P, Pacini G, Hartmann B, Holst JJ, MacKenzie C, Bindels LB, Martinez I, Walter J, Henrich B, Schloot NC, Roden M.

Diabetes Care. 2015 Oct;38(10):1827-34. doi: 10.2337/dc14-2690. Epub 2015 Jun 17.

PMID:
26084343
14.

Foodborne transmission of bovine spongiform encephalopathy to non-human primates results in preclinical rapid-onset obesity.

Strom A, Yutzy B, Kruip C, Ooms M, Schloot NC, Roden M, Scott FW, Loewer J, Holznagel E.

PLoS One. 2014 Aug 4;9(8):e104343. doi: 10.1371/journal.pone.0104343. eCollection 2014.

15.

Leukocyte profiles differ between type 1 and type 2 diabetes and are associated with metabolic phenotypes: results from the German Diabetes Study (GDS).

Menart-Houtermans B, Rütter R, Nowotny B, Rosenbauer J, Koliaki C, Kahl S, Simon MC, Szendroedi J, Schloot NC, Roden M; German Diabetes Study Group.

Diabetes Care. 2014 Aug;37(8):2326-33. doi: 10.2337/dc14-0316.

PMID:
25061140
16.

Macro- and microvascular outcomes in patients with type 2 diabetes treated with rapid-acting insulin analogues or human regular insulin: a retrospective database analysis.

Rathmann W, Schloot NC, Kostev K, Reaney M, Zagar AJ, Haupt A.

Exp Clin Endocrinol Diabetes. 2014 Feb;122(2):92-9. doi: 10.1055/s-0033-1363684. Epub 2014 Feb 20.

PMID:
24558019
17.

DiaPep277® and immune intervention for treatment of type 1 diabetes.

Schloot NC, Cohen IR.

Clin Immunol. 2013 Dec;149(3):307-16. doi: 10.1016/j.clim.2013.09.001. Epub 2013 Sep 11. Review.

PMID:
24090708
18.

The systemic immune network in recent onset type 1 diabetes: central role of interleukin-1 receptor antagonist (DIATOR Trial).

Kolb H, Lückemeyer K, Heise T, Herder C, Schloot NC, Koenig W, Heinemann L, Martin S; DIATOR Study Group.

PLoS One. 2013 Aug 26;8(8):e72440. doi: 10.1371/journal.pone.0072440. eCollection 2013.

19.

Meal replacement reduces insulin requirement, HbA1c and weight long-term in type 2 diabetes patients with >100 U insulin per day.

Kempf K, Schloot NC, Gärtner B, Keil R, Schadewaldt P, Martin S.

J Hum Nutr Diet. 2014 Apr;27 Suppl 2:21-7. doi: 10.1111/jhn.12145. Epub 2013 Aug 2.

PMID:
23909831
20.

Fatty acids modulate cytokine and chemokine secretion of stimulated human whole blood cultures in diabetes.

Simon MC, Bilan S, Nowotny B, Dickhaus T, Burkart V, Schloot NC.

Clin Exp Immunol. 2013 Jun;172(3):383-93. doi: 10.1111/cei.12071.

21.

Fasting and meal-stimulated residual beta cell function is positively associated with serum concentrations of proinflammatory cytokines and negatively associated with anti-inflammatory and regulatory cytokines in patients with longer term type 1 diabetes.

Pham MN, Kolb H, Battelino T, Ludvigsson J, Pozzilli P, Zivehe F, Roden M, Mandrup-Poulsen T, Schloot NC; European C-Peptide Trial.

Diabetologia. 2013 Jun;56(6):1356-63. doi: 10.1007/s00125-013-2883-3. Epub 2013 Mar 15.

PMID:
23494449
22.

Mechanisms underlying the onset of oral lipid-induced skeletal muscle insulin resistance in humans.

Nowotny B, Zahiragic L, Krog D, Nowotny PJ, Herder C, Carstensen M, Yoshimura T, Szendroedi J, Phielix E, Schadewaldt P, Schloot NC, Shulman GI, Roden M.

Diabetes. 2013 Jul;62(7):2240-8. doi: 10.2337/db12-1179. Epub 2013 Mar 1.

23.

Spontaneous obesity-linked type 2 diabetes in the absence of islet amyloid in a cynomolgus monkey infected with bovine spongiform encephalopathy.

Strom A, Yutzy B, Kruip C, Völker I, Schloot NC, Roden M, Scott FW, Löwer J, Holznagel E.

Vet Pathol. 2013 Sep;50(5):909-13. doi: 10.1177/0300985813476057. Epub 2013 Feb 4.

PMID:
23381923
24.

Serum adipokines as biomarkers of beta-cell function in patients with type 1 diabetes: positive association with leptin and resistin and negative association with adiponectin.

Pham MN, Kolb H, Mandrup-Poulsen T, Battelino T, Ludvigsson J, Pozzilli P, Roden M, Schloot NC; European C-Peptide Trial.

Diabetes Metab Res Rev. 2013 Feb;29(2):166-70. doi: 10.1002/dmrr.2378.

PMID:
23197433
25.

Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial).

Strom A, Kolb H, Martin S, Herder C, Simon MC, Koenig W, Heise T, Heinemann L, Roden M, Schloot NC; DIATOR Study Group.

PLoS One. 2012;7(3):e33108. doi: 10.1371/journal.pone.0033108. Epub 2012 Mar 20.

26.

Cellular interferon-γ and interleukin-13 immune reactivity in type 1, type 2 and latent autoimmune diabetes: action LADA 6.

Strom A, Menart B, Simon MC, Pham MN, Kolb H, Roden M, Pozzilli P, Leslie RD, Schloot NC.

Cytokine. 2012 May;58(2):148-51. doi: 10.1016/j.cyto.2012.01.002. Epub 2012 Feb 3.

PMID:
22305546
27.

Increased serum concentrations of adhesion molecules but not of chemokines in patients with Type 2 diabetes compared with patients with Type 1 diabetes and latent autoimmune diabetes in adult age: action LADA 5.

Pham MN, Hawa MI, Roden M, Schernthaner G, Pozzilli P, Buzzetti R, Scherbaum WA, Seissler J, Hunter S, Leslie RD, Kolb H, Schloot NC; Action LADA Study Group.

Diabet Med. 2012 Apr;29(4):470-8. doi: 10.1111/j.1464-5491.2011.03546.x.

PMID:
22150724
28.

Association between age, IL-10, IFNγ, stimulated C-peptide and disease progression in children with newly diagnosed Type 1 diabetes.

Kaas A, Pfleger C, Kharagjitsingh AV, Schloot NC, Hansen L, Buschard K, Koeleman BP, Roep BO, Mortensen HB, Alizadeh BZ; Hvidoere Study Group on Childhood Diabetes.

Diabet Med. 2012 Jun;29(6):734-41. doi: 10.1111/j.1464-5491.2011.03544.x.

PMID:
22150609
29.

Comparison of cryopreservation methods on T-cell responses to islet and control antigens from type 1 diabetic patients and controls.

Brooks-Worrell B, Tree T, Mannering SI, Durinovic-Bello I, James E, Gottlieb P, Wong S, Zhou Z, Yang L, Cilio CM, Reichow J, Menart B, Rutter R, Schreiner R, Pham M, Petrich de Marquesini L, Lou O, Scotto M, Mallone R, Schloot NC; T-Cell Workshop Committee, Immunology of Diabetes Society.

Diabetes Metab Res Rev. 2011 Nov;27(8):737-45. doi: 10.1002/dmrr.1245.

PMID:
22069253
30.

Immunology of Diabetes Society T-Cell Workshop: HLA class II tetramer-directed epitope validation initiative.

James EA, Mallone R, Schloot NC, Gagnerault MC, Thorpe J, Fitzgerald-Miller L, Reichow J, Wagner R, Pham MN, Jospe N, Lou O, Gottlieb PA, Brooks-Worrell BM, Durinovic-Belló I; T-Cell Workshop Committee, Immunology of Diabetes Society.

Diabetes Metab Res Rev. 2011 Nov;27(8):727-36. doi: 10.1002/dmrr.1244.

PMID:
22069252
31.

Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial.

Martin S, Herder C, Schloot NC, Koenig W, Heise T, Heinemann L, Kolb H; DIATOR Study Group.

PLoS One. 2011 Mar 11;6(3):e17554. doi: 10.1371/journal.pone.0017554.

32.

Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4.

Pham MN, Hawa MI, Pfleger C, Roden M, Schernthaner G, Pozzilli P, Buzzetti R, Scherbaum WA, Seissler J, Kolb H, Hunter S, Leslie RD, Schloot NC; Action LADA Study Group.

Diabetologia. 2011 Jul;54(7):1630-8. doi: 10.1007/s00125-011-2088-6. Epub 2011 Feb 24. Erratum in: Diabetologia. 2012 Feb;55(2):534. Scherbaum, W [corrected to Scherbaum, W A].

PMID:
21347621
33.

[Recent advances in the treatment of type 1 diabetes mellitus].

Schloot NC, Roden M, Bornstein SR, Brendel MD.

Dtsch Med Wochenschr. 2011 Feb;136(5):172-5. doi: 10.1055/s-0031-1272502. Epub 2011 Jan 26. Review. German.

PMID:
21271474
34.

Circulating cytokines are associated with human islet graft function in type 1 diabetes.

Pfleger C, Schloot NC, Brendel MD, Burkart V, Hogenkamp V, Bretzel RG, Jaeger C, Eckhard M.

Clin Immunol. 2011 Feb;138(2):154-61. doi: 10.1016/j.clim.2010.10.008. Epub 2010 Nov 19.

PMID:
21094094
35.

High affinity binding of hydrophobic and autoantigenic regions of proinsulin to the 70 kDa chaperone DnaK.

Burkart V, Siegenthaler RK, Blasius E, Vandenbroeck K, Alloza I, Fingberg W, Schloot NC, Christen P, Kolb H.

BMC Biochem. 2010 Nov 8;11:44. doi: 10.1186/1471-2091-11-44.

36.

Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society.

Mallone R, Mannering SI, Brooks-Worrell BM, Durinovic-Belló I, Cilio CM, Wong FS, Schloot NC; T-Cell Workshop Committee, Immunology of Diabetes Society.

Clin Exp Immunol. 2011 Jan;163(1):33-49. doi: 10.1111/j.1365-2249.2010.04272.x. Epub 2010 Oct 5. Review.

37.

Current approaches to measuring human islet-antigen specific T cell function in type 1 diabetes.

Mannering SI, Wong FS, Durinovic-Belló I, Brooks-Worrell B, Tree TI, Cilio CM, Schloot NC, Mallone R; Immunology of Diabetes Society T-Cell Workshop Committee.

Clin Exp Immunol. 2010 Nov;162(2):197-209. doi: 10.1111/j.1365-2249.2010.04237.x. Epub 2010 Sep 15. Review.

38.

Association of adiponectin, interleukin (IL)-1ra, inducible protein 10, IL-6 and number of islet autoantibodies with progression patterns of type 1 diabetes the first year after diagnosis.

Kaas A, Pfleger C, Hansen L, Buschard K, Schloot NC, Roep BO, Mortensen HB; Hvidøre Study Group on Childhood Diabetes.

Clin Exp Immunol. 2010 Sep;161(3):444-52. doi: 10.1111/j.1365-2249.2010.04193.x.

39.

[Immunological intervention to preserve beta-cell function in type 1 diabetes].

Schloot NC.

Dtsch Med Wochenschr. 2010 May;135(18):915-21. doi: 10.1055/s-0030-1253678. Epub 2010 Apr 27. Review. German.

PMID:
20425677
40.

Monocyte gene-expression profiles associated with childhood-onset type 1 diabetes and disease risk: a study of identical twins.

Beyan H, Drexhage RC, van der Heul Nieuwenhuijsen L, de Wit H, Padmos RC, Schloot NC, Drexhage HA, Leslie RD.

Diabetes. 2010 Jul;59(7):1751-5. doi: 10.2337/db09-1433. Epub 2010 Apr 14.

41.

Effect of combined oral proteases and flavonoid treatment in subjects at risk of Type 1 diabetes.

Kempf K, Manzo G, Hanifi-Moghaddam P, Kappler S, Seissler J, Jaeger C, Boehm B, Roden M, Kolb H, Martin S, Schloot NC; PRODIAB Study Group.

Diabet Med. 2009 Dec;26(12):1309-10. doi: 10.1111/j.1464-5491.2009.02879.x. No abstract available.

PMID:
20002490
42.

Challenges in developing endpoints for type 1 diabetes intervention studies.

Cernea S, Raz I, Herold KC, Hirshberg B, Roep BO, Schatz DA, Fleming GA, Pozzilli P, Little R, Schloot NC, Leslie RD, Skyler JS, Palmer JP; D-Cure Workshop.

Diabetes Metab Res Rev. 2009 Nov;25(8):694-704. doi: 10.1002/dmrr.1002. Review.

PMID:
19771545
43.

Interferon beta treatment does not induce organ-specific autoantibodies in multiple sclerosis.

Menge T, Schloot NC, Schott M, Hemmer B, Wiendl H, Roden M, Hartung HP, Kieseier BC.

Neurology. 2009 Sep 15;73(11):900-2. doi: 10.1212/WNL.0b013e3181b78460. No abstract available.

PMID:
19752459
44.

Association of T-cell reactivity with beta-cell function in recent onset type 1 diabetes patients.

Pfleger C, Meierhoff G, Kolb H, Schloot NC; p520/521 Study Group.

J Autoimmun. 2010 Mar;34(2):127-35. doi: 10.1016/j.jaut.2009.08.004. Epub 2009 Sep 9.

PMID:
19744828
45.

Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study.

Herder C, Brunner EJ, Rathmann W, Strassburger K, Tabák AG, Schloot NC, Witte DR.

Diabetes Care. 2009 Mar;32(3):421-3. doi: 10.2337/dc08-1161. Epub 2008 Dec 10.

46.

Diabetes classification: grey zones, sound and smoke: Action LADA 1.

Leslie RD, Kolb H, Schloot NC, Buzzetti R, Mauricio D, De Leiva A, Yderstraede K, Sarti C, Thivolet C, Hadden D, Hunter S, Schernthaner G, Scherbaum W, Williams R, Pozzilli P.

Diabetes Metab Res Rev. 2008 Oct;24(7):511-9. doi: 10.1002/dmrr.877. Review.

PMID:
18615859
47.

Distinct monocyte gene-expression profiles in autoimmune diabetes.

Padmos RC, Schloot NC, Beyan H, Ruwhof C, Staal FJ, de Ridder D, Aanstoot HJ, Lam-Tse WK, de Wit H, de Herder C, Drexhage RC, Menart B, Leslie RD, Drexhage HA; LADA Consortium.

Diabetes. 2008 Oct;57(10):2768-73. doi: 10.2337/db08-0496. Epub 2008 Jul 3.

48.

Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes.

Pfleger C, Kaas A, Hansen L, Alizadeh B, Hougaard P, Holl R, Kolb H, Roep BO, Mortensen HB, Schloot NC; Hvidøre Study Group On Childhood Diabetes.

Clin Immunol. 2008 Jul;128(1):57-65. doi: 10.1016/j.clim.2008.03.458. Epub 2008 Apr 22.

PMID:
18434252
49.

Circulating chemokines in patients with autoimmune thyroid diseases.

Domberg J, Liu C, Papewalis C, Pfleger C, Xu K, Willenberg HS, Hermsen D, Scherbaum WA, Schloot NC, Schott M.

Horm Metab Res. 2008 Jun;40(6):416-21. doi: 10.1055/s-2008-1073151. Epub 2008 Apr 14. Erratum in: Horm Metab Res. 2008 Jun;40(6):433. Chao, L [corrected to Liu, C].

PMID:
18415893
50.

Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes.

Pfleger C, Mortensen HB, Hansen L, Herder C, Roep BO, Hoey H, Aanstoot HJ, Kocova M, Schloot NC; Hvidøre Study Group on Childhood Diabetes.

Diabetes. 2008 Apr;57(4):929-37. doi: 10.2337/db07-1697. Epub 2008 Feb 25.

Supplemental Content

Loading ...
Support Center